Loading
Everything in development, the open problems and what is being done about them, the roadmaps, and what changed on this record.
What is in development for Stage IIB and IIC melanoma, drawn from the whole corpus: 8 items. Drugs are grouped by the most advanced trial phase they have reached anywhere; approved treatments sit under standard of care. Technologies are the methods being tested for this cancer, trials are the studies recorded here, and ideas are proposals not yet in a trial.
Roughly four in five patients would have been cured by surgery alone and cannot yet be told apart from the fifth.
No overall survival benefit has yet been shown for adjuvant therapy in stage II.
Permanent endocrine side effects in a minority weigh heavily when the absolute benefit is a few percentage points.
Nothing recorded yet.
Nothing recorded yet.
Also on OnCo: Side effects by symptom · Immune-related side effects · Toxicity compare · Survivorship planner.
Dated changes read from the records linked to this cancer: approvals, regulatory steps, reported trials, guideline versions and milestones. Newest first; no date is inferred.
On EdgeAll 7 changes by month →When this page itself was last checked or edited.
RFS and DMFS significantly improved (HRs pending presentation).
A milestone in how this cancer is treated.
A milestone in how this cancer is treated.
RFS and DMFS improved; 5-year benefit sustained (ESMO 2025).
A milestone in how this cancer is treated.